Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.39 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
| ▸ | FYN | P06241 | 1/20 | 0.37 |
| ▸ | PLK1 | P53350 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.36 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.36 |
| ▸ | ALDH1A2 | O94788 | 1/20 | 0.35 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.35 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22845397 | 0.81 | KDM4E (0.43) | PGRALDH1A1MEN1KMT2A | |
| SCHEMBL22717409 | 0.78 | MAPK1 (0.40) | RENNPC1RAB9APDE7AKDM4C | |
| SCHEMBL22845222 | 0.76 | REN (0.41) | RENNPC1RAB9APDE7AKDM4C | |
| SCHEMBL22845487 | 0.68 | HTR2C (0.38) | NPC1RAB9A | |
| SCHEMBL22845203 | 0.68 | KDM5A (0.42) | RENPGRALDH1A1MEN1KMT2A | |
| SCHEMBL22845300 | 0.68 | KDM4C (0.48) | KDM4CPLK1ALDH1A1MAPK8MAPK9 | |
| SCHEMBL22845268 | 0.68 | ALDH1A1 (0.49) | RAB9AALDH1A1MEN1KMT2A | |
| SCHEMBL22845485 | 0.68 | ALDH1A1 (0.41) | PGRALDH1A1ALDH1A2ALDH1A3 | |
| SCHEMBL4193981 | 0.67 | REN (0.48) | RENNPC1RAB9APDE7AKDM4C | |
| SCHEMBL22172011 | 0.66 | KDM4C (0.47) | RENKDM4CALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220000874-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2022-01-06 | — | — | US | disclosed |
| US-11136321-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2021-10-05 | — | — | US | disclosed |
| US-20200407361-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2020-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220000874-A1 | TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CEL | REN 29/4885NPC1 5/4885RAB9A 488/4885 |
| US-11136321-B2 | Tricyclic compounds | SLC10A1, PKD1, CEL | REN 29/4885NPC1 5/4885RAB9A 488/4885 |
| US-20200407361-A1 | TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CEL | REN 29/4885NPC1 5/4885RAB9A 488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.